These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of o,p'-DDD on plasma ACTH concentration in Cushing's disease. Bruno OD; Hoschoian JC; Andrada JA Medicina (B Aires); 1979; 39(2):229-34. PubMed ID: 228150 [No Abstract] [Full Text] [Related]
5. [Plasma determination of O,P-DDD. Clinical value]. Leutenegger M; Caron J; Couchot J; Gross A; Maes B; Enger A; Millart H Nouv Presse Med; 1977 Feb; 6(7):566. PubMed ID: 840640 [No Abstract] [Full Text] [Related]
6. [Information value of methods for determining glucocorticoids in patients with Itsenko-Cushing disease]. Bezverkhaia TP; Cheban AK; Verkhogliadova LM; Savitskaia VV Vrach Delo; 1987 Apr; (4):82-4. PubMed ID: 3617651 [No Abstract] [Full Text] [Related]
7. [Treatment of Itsenko-Cushing disease (review of the literature)]. Komissarenko IV; Efimov AS Probl Endokrinol (Mosk); 1973; 19(1):108-12. PubMed ID: 4349070 [No Abstract] [Full Text] [Related]
8. [Diagnosis and therapy of endogenic hypercortisolism (Cushing's syndrome)]. Meng W; Meng S Z Arztl Fortbild (Jena); 1972 Oct; 66(20):1025-31. PubMed ID: 4346727 [No Abstract] [Full Text] [Related]
9. [Synthetic cortisol antagonists in the treatment of adrenal gland hypercortisolism. Results of 8 years of use]. Bricaire H; Luton JP Therapie; 1974; 29(5):645-58. PubMed ID: 4462221 [No Abstract] [Full Text] [Related]
10. [Experiences with Lysodren therapy of Cushing's syndrome in the dog (1)]. Opitz M; Lettow E; Loppnow H; Grevel V Tierarztl Prax; 1983; 11(3):369-84. PubMed ID: 6636131 [No Abstract] [Full Text] [Related]
11. Current therapeutic concepts--Cushing's syndrome. Kishi DT J Am Pharm Assoc; 1975 May; 15(5):261-70. PubMed ID: 164494 [No Abstract] [Full Text] [Related]
12. o,p'-DDD (mitotane) treatment of canine pituitary-dependent hyperadrenocorticism. Peterson ME J Am Vet Med Assoc; 1983 Mar; 182(5):527-8. PubMed ID: 6300010 [No Abstract] [Full Text] [Related]
13. [Therapeutic effect of adrenocortical inhibitor-chloditan in Itsenko-Cushing disease]. Komissarenko IV; Slavnov VN; Rybakov SI; Cheban AK; Luchitskiĭ EV Ter Arkh; 1977; 49(1):61-4. PubMed ID: 867241 [No Abstract] [Full Text] [Related]
14. Short stature as the only clinical sign of Cushing's syndrome. Lee PA; Weldon VV; Migeon CJ J Pediatr; 1975 Jan; 86(1):89-91. PubMed ID: 162955 [No Abstract] [Full Text] [Related]
15. Adrenal and pituitary effects of mitotane in Cushing's syndrome. Kasperlik-Załuska A; Jeske W; Migdalska B Endokrynol Pol; 1986; 37(1):17-21. PubMed ID: 3015579 [No Abstract] [Full Text] [Related]
17. [Experiences with Lysodren treatment of Cushing's syndrome in dogs]. Opitz M; Lettow E; Loppnow H; Grevel V Tierarztl Prax; 1983; 11(4):507-20. PubMed ID: 6658774 [No Abstract] [Full Text] [Related]
18. [Glucocorticoid function of the adrenals in patients with Itsenko-Cushing disease treated with chloditane]. Slavnov VN; Luchitskiĭ EV; Komissarenko IV; Cheban AK Klin Med (Mosk); 1979 Jan; 57(1):60-4. PubMed ID: 439802 [No Abstract] [Full Text] [Related]